Insulet

YTD

ALL

Trade Insulet 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.

CEO

Ashley A. McEvoy

CEOAshley A. McEvoy

Employees

3,900

Employees3,900

Headquarters

Acton, Massachusetts

HeadquartersActon, Massachusetts

Founded

2000

Founded2000

Employees

3,900

Employees3,900

PODD Key Statistics

Market cap

22.62B

Market cap22.62B

Price-Earnings ratio

56.59

Price-Earnings ratio56.59

Dividend yield

—

Dividend yield—

Average volume

1.18M

Average volume1.18M

High today

$327.96

High today$327.96

Low today

$313.39

Low today$313.39

Open price

$313.39

Open price$313.39

Volume

966.61K

Volume966.61K

52 Week high

$327.96

52 Week high$327.96

52 Week low

$170.67

52 Week low$170.67

PODD News

TipRanks 1h

Director’s Major Stock Sale Shakes Up Insulet!

New insider activity at Insulet ( (PODD) ) has taken place on May 15, 2025. Confident Investing Starts Here: Quickly and easily unpack a company's performance...

TipRanks 4d

Wall Street Analysts Turn Bullish on Insulet After Strong Q1 Earnings

Insulet Corporation (PODD), the healthcare company known for its insulin delivery system, has experienced a phenomenal week, encapsulated in its stock soaring a...

Simply Wall St 5d

Insulet (NasdaqGS:PODD) Announces $125M Buyback, Raises Revenue Guidance For 2025

recently announced significant corporate developments including a share repurchase program and raised revenue guidance for 2025, indicating a focus on growth an...

Analyst ratings

78%

of 27 ratings

Buy

77.8%

Hold

22.2%

Sell

More PODD News

TipRanks 6d

Insulet’s Strong Financial Performance and Growth Potential Drive Buy Rating

William Blair analyst Margaret Kaczor has maintained their bullish stance on PODD stock, giving a Buy rating today. Margaret Kaczor has given her Buy rating du...

People also own

Based on the portfolios of people who own PODD. This list is generated using Robinhood data, and it’s not a recommendation.